Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 1.00 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.74 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.74 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.62 |
| ▸ | GRIK1 | P39086 | 9/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.52 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.48 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.48 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL175940 | 1.00 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL8568063 | 1.00 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| D-Leucine SCHEMBL9449950 | 1.00 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL20362356 | 1.00 | — | — | |
| Leucine SCHEMBL3888 | 1.00 | — | — | |
| D-Leucine SCHEMBL42012 | 1.00 | — | — | |
| Leucine SCHEMBL25241602 | 1.00 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL8568060 | 1.00 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL2478164 | 1.00 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| D-Leucine SCHEMBL9100148 | 1.00 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1520073-B1 | TRIAZINNYLAMINOSTILBENE DISULPHONIC ACID MIXTURES | BASF SE (DE) | 2012-01-18 | — | — | EP | claimed |
| EP-1820793-B1 | Process of stabilization of nucleic acids in biological materials | QIAGEN GMBH (DE) | 2011-09-14 | — | — | EP | claimed |
| EP-2292837-A1 | Triazinylaminostilbene disulphonic acid mixtures | BASF SE (DE) | 2011-03-09 | — | — | EP | claimed |
| US-7585333-B2 | Fluorescent whitening agent, for whitening synthetic or natural organic materials, especially paper and for the fluorescent whitening and improvement of sun protection factors of textile materials | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2009-09-08 | — | — | US | claimed |
| US-20080307585-A1 | Fluorescent whitening agent, for whitening synthetic or natural organic materials, especially paper and for the fluorescent whitening and improvement of sun protection factors of textile materials | CIBA SPECIALTY CHEMICALS CORP. | 2008-12-18 | — | — | US | claimed |
| US-20050203221-A1 | Whitening pigments | CIBA SPECIALTY CHEMICALS CORP. | 2005-09-15 | — | — | US | claimed |
| US-8920781-B2 | Carrier particles for use in dry powder inhalers | VECTURA LIMITED (GB) | 2014-12-30 | — | — | US | disclosed |
| US-8269037-B2 | Absorption medium for removing acid gases which comprises amino acid and acid promoter | BASF SE (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-2449488-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES Life Sciences AG (AT) | 2012-05-09 | — | — | EP | disclosed |
| EP-1520073-B1 | TRIAZINNYLAMINOSTILBENE DISULPHONIC ACID MIXTURES | BASF SE (DE) | 2012-01-18 | — | — | EP | disclosed |
| EP-2407540-A1 | Method for purifying a target nucleic acid | Qiagen GmbH (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-8034166-B2 | Carbon dioxide absorbent requiring less regeneration energy | BASF SE (DE) | 2011-10-11 | — | — | US | disclosed |
| WO-2011086195-A1 | METHOD FOR ISOLATING SMALL RNA | QIAGEN GMBH (DE) | 2011-07-21 | — | — | WO | disclosed |
| US-7718163-B2 | Includes additive material on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the inhaler; an inhalant includes crystalline milk sugar carrier,leucine additive and beclomethasone dipropionate inhalant | VECTURA LIMITED (01696917) (GB) | 2010-05-18 | — | — | US | disclosed |
| US-7011818-B2 | Carrier particles for use in dry powder inhalers | VECTURA LIMITED (GB) | 2006-03-14 | — | — | US | disclosed |
| US-20060029552-A1 | Includes additive material on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the inhaler; an inhalant includes crystalline milk sugar carrier,leucine additive and beclomethasone dipropionate inhalant | VECTURA LIMITED (GB) | 2006-02-09 | — | — | US | disclosed |
| US-20050203221-A1 | Whitening pigments | CIBA SPECIALTY CHEMICALS CORP. | 2005-09-15 | — | — | US | disclosed |
| US-20030170183-A1 | Promotes the release of the active particles from the carrier particles on actuation of the inhaler; efficiency | VECTURA LIMITED (GB) | 2003-09-11 | — | — | US | disclosed |
| US-6521260-B1 | Magnesium stearate additive material being on the surfaces of the carrier particles | VECTURA LIMITED (GB) | 2003-02-18 | — | — | US | disclosed |
| US-5134073-A | Culture product of zoogloea ramigera | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1992-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203221-A1 | Whitening pigments | YTHDC1, TRPC1, AOC1 | SLC7A5 894/4885SLC1A2 3382/4885SLC1A3 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.